Arcellx announced that the FDA has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.
[Arcellx]
josh@comocreative.com. (2021, April 6). Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma. Arcellx. https://arcellx.com/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therapy-utilizing-the-companys-arc-sparx-platform-for-the-treatment-of-multiple-myeloma/ Cite
0